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Immune cells and cells activated by the inflammatory cytokine interferon express variant protea-
somes called immunoproteasomes that are characterized by unique catalytic subunits. Seifert
et al. (2010) now show in mouse models of inflammatory disease that immunoproteasomes help
prevent the accumulation of harmful protein aggregates.The proteasome recognizes and de-
grades proteins substrates modified with
polyubiquitin chains, and small protein
fragments generated by the proteasome
can be used by major histocompatibility
complex (MHC) class I molecules for the
display of antigens to the immune system.
However, this simple picture is compli-
cated by the presence of genes at the
MHC locus that encode two variant cata-
lytic subunits of the proteasome, lmp2/b1i
and lmp7/b5i. These two subunits (along
with a third one,MECL1/b2i) are abundant
in cells of the immune system and are ex-
pressed in other cell types after exposure
to the cytokine interferon g. Conse-
quently, immune cells expressing these
variant catalytic subunits have special-
ized proteasomes, called immunoprotea-
somes. The question is ‘‘why’’? In this
issue, Seifert et al. (2010) reveal a sur-
prising role for immunoproteasomes—
the prevention of protein aggregate
formation during inflammation.
Prior work has indicated that immuno-
proteasomes promote the generation of
relevant peptides for presentation by
MHC class I molecules, and in vitro exper-
iments demonstrate that immunoprotea-
somes (containing lmp2 and lmp7) to
a certain extent produce different
peptides than standard proteasomes.
However, the phenotypes of mice lacking
lmp2 or lmp7 are very subtle, suggesting
that immunoproteasomes are likely to
have a minor role at most in antigen pro-
cessing (Kloetzel and Ossendorp, 2004).
It remains unclear why immune responses
would improve when distinct peptides are
presented by MHC class I molecules on
immune cells versus other cells (Van denEynde and Morel, 2001), leaving the func-
tion of immunoproteasomes an enigma.
Priorwork has also shown that immuno-
proteasomes are more active than stan-
dard proteasomes. The proteasome is in
fact a slow protease (Yewdell, 2001; Yew-
dell et al., 2003), and its activity becomes
rate limiting when the amount of substrate
presented for degradation exceeds that
which occurs under steady-state condi-
tions. The findings of Seifert et al. now
suggest that the enhanced activity of the
immunoproteasomes (relative to standard
proteasomes) prevents the accumulation
of degradation substrates that would
otherwise aggregate during inflammation
(Figure 1).
An increase protein synthesis results
from activation of the mTOR pathway
downstream of stimulation by the inflam-
matory cytokine interferon and numerous
other stimuli, including ionizing radiation
and insulin (Reits et al., 2006; Ma and
Blenis, 2009). A large fraction of newly
generated proteins are defective in
folding, translation, or assembly and
thus need to be destroyed in order to
prevent the formation of potentially
harmful aggregates. These products are
collectively called defective ribosomal
products (DRiPs). Seifert and colleagues
now show that immunoproteasomes are
essential for the degradation of DRiPs re-
sulting from mTOR-induced translation
after interferon g exposure.
At least two mechanisms—protein
production and protein damage—con-
tribute to the generation of an interferon
g-induced protein pool that requires
degradation by the immunoproteasome.
Similar to ionizing radiation (Reits et al.,Cell 142006), interferon g produces radicals,
presumably by activating the inducible ni-
tric oxide synthase (iNOS) system. The re-
sulting radicals lead to oxidative-protein
damage. The authors show that newly
synthesized proteins are very sensitive
to oxygen radicals (although existing
proteins should also be modified given
that radicals are not selective). The
authors show that the damaged proteins
further enhance the pool of DRiPs that
cannot be fully handled by the normal pro-
teasome but instead require immunopro-
teasomes for efficient destruction.
In the ‘‘substrate recognition-ubiquiti-
nation-degradation’’ reaction cascade
ubiquitin ligation should be close to
limiting. Indeed, the E2/E3 ligase system
determines substrate recognition for ubiq-
uitin transfer, and the proteasome only
performs the final act of protein degrada-
tion (Strehl et al., 2005; Ravid and Hoch-
strasser, 2008). Seifert et al. show that
interferon g upregulates expression of
a series of E3 ligases and one E2 ligase
UBE2C6 that appears to be required for
efficient DRiP degradation. The authors
also consider the ubiquitin-proteasome
cycle in a broader context. The amount
of free ubiquitin in cells is very small
(5% of total ubiquitin) (Dantuma et al.,
2006). The rest is coupled to substrates
as mono- or polyubiquitin, and the ubiqui-
tin supply is largely obtained fromubiquiti-
nated histones. Histone deubiquitination
is observed within hours of proteasome
inhibition, heat shock (Dantuma et al.,
2006), and interferon g treatment (Seifert
et al., 2010). Widespread histone deubi-
quitination should result in alterations in
the transcriptome.2, August 20, 2010 ª2010 Elsevier Inc. 517
Figure 1. Immunoproteasomes Prevent Protein Aggregate
Formation
Exposure of cells to the inflammatory cytokine interferon induces a cascade of
events including selective upregulation of major histocompatibility complex
(MHC) class I, E3 and E2 UBE2C6 ubiquitin ligases, and immunoproteasome
subunits b1i, b2i, and b5i. These assist in the handling of enhanced amounts
of substrate that are the result of activation of the mTOR pathway. mTOR
enhances translation, leading to the production of both nascent proteins and
proteins that fail to form correctly, known as defective ribosomal products
(DRiPs). Protein-damaging oxygen radicals are also formed upon interferon
induction. Ubiquitin is present in limiting amounts for DRiP modification and
is acquired from ubiquitin-modified histones. Deubiquitination of histones
should affect the transcriptome. The normal proteasome cannot handle the
enhanced pool of proteasome substrates, resulting in accumulated damaged
protein aggregates and neuronal inflammatory diseases. The induced immuno-
proteasome has higher activity and is thus able to more efficiently degrade the
substrate pool. Peptide fragments resulting from proteasome activity can serve
in antigen presentation by MHC class I molecules.How important is the
dynamic exchange of stan-
dard proteasomes for immu-
noproteasomes in response
to immunological stress? Sei-
fert et al. test this by exam-
ining two mouse models of
inflammation: inflammation
induced by lipopolysaccha-
ride (a component of the
outer wall of Gram-negative
bacteria) and experimental
autoimmune encephalomy-
elitis (EAE; a demyelinating
disorder often used as
a model for multiple scle-
rosis). In these models, they
observe elevated levels of
oxidized proteins and poly-
ubiquitin in liver and brain of
immunoproteasome-deficient
mice (that is, mice lacking
lmp7/b5i). In addition, the
inflammation induced by EAE
is more severe in the absence
of the immunoproteasome.
These observations suggest
that immunoproteasome in-
duction during inflammation
prevents harmful protein ag-
gregation. Interestingly, the
exchange of standard pro-
teasome for immunoprotea-
somes is a slow process,
and, prior to assembly of the
immunoproteasome, DRiPs
accumulate and form aggre-
gates. At a later point in
time, immunoproteasomes
are able to dissolve and de-
grade the accumulated ag-
gregates, which implies that
the aggregates are dynamic,
a possibility that warrants
future study. Why immuno-
proteasomes are not always
expressed to counter accu-
mulation of DRiPs and othersubstrates is unclear. Possibly, constitu-
tive immunoproteasome expression is
deleterious in contexts other than the
immune system. The fact that organisms
such as yeast, flies, and nematodes only518 Cell 142, August 20, 2010 ª2010 Elseviehave one type of proteasome suggests
that immunoproteasomes are an evolu-
tionary adaption to particular conditions,
such as the ones described by Seifert
and colleagues.r Inc.The findings of Seifert
and colleagues provide a
new explanation for inflam-
mation-induced tissue pa-
thology. It also provides
evidence that immunoprotea-
somes are important for the
control of diseases induced
by inflammation, including
EAE. Further investigation
will determine whether the
dynamic exchange of protea-
somes for immunoprotea-
somes fails under other
conditions and how the im-
munoproteasome is involved
in human pathologies.REFERENCES
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